Holen Sie sich die Stockscreener-App
24.88
4.12%
-1.31
Handel nachbörslich:
26.10
1.22
+4.90%
Schlusskurs vom Vortag:
$26.19
Offen:
$25.98
24-Stunden-Volumen:
381.34K
Relative Volume:
0.54
Marktkapitalisierung:
$908.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.03%
1M Leistung:
+5.68%
6M Leistung:
+155.18%
1J Leistung:
+2.95%
1-Tages-Spanne:
$24.87
$26.75
1-Wochen-Bereich:
$25.14
$27.72
52-Wochen-Spanne:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
99 HIGH STREET, BOSTON
Vergleichen Sie RAPP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
24.88 | 1.22B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-16 | Eingeleitet | Truist | Buy |
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Eingeleitet | Jefferies | Buy |
| 2024-07-02 | Eingeleitet | Stifel | Buy |
| 2024-07-02 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
Has Rapport Therapeutics Inc. found a price floorMarket Movement Recap & Accurate Entry and Exit Point Alerts - newser.com
Published on: 2025-10-14 03:02:31 - newser.com
Volatility clustering patterns for Rapport Therapeutics Inc.Stop Loss & Verified Momentum Stock Watchlist - newser.com
How to recover losses in Rapport Therapeutics Inc. stock2025 Bull vs Bear & Safe Swing Trade Setups - newser.com
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) PT at $35.33 - Defense World
Statistical indicators supporting Rapport Therapeutics Inc.’s strengthSell Signal & AI Based Trade Execution Alerts - newser.com
Analyzing net buyer seller activity in Rapport Therapeutics Inc.Trade Analysis Summary & Safe Entry Trade Reports - newser.com
Is Rapport Therapeutics Inc. trending in predictive chart models2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Can volume confirm reversal in Rapport Therapeutics Inc.2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
Multi factor analysis applied to Rapport Therapeutics Inc.Weekly Gains Report & Growth Focused Entry Point Reports - newser.com
Rapport Therapeutics Inc. stock chart pattern explainedMarket Risk Analysis & Weekly High Return Opportunities - newser.com
Published on: 2025-10-12 22:23:14 - newser.com
Identifying reversal signals in Rapport Therapeutics Inc.Weekly Trading Summary & Risk Controlled Stock Pick Alerts - newser.com
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Key metrics from Rapport Therapeutics Inc.’s quarterly dataJuly 2025 Levels & Risk Controlled Daily Plans - newser.com
Smart tools for monitoring Rapport Therapeutics Inc.’s price actionJuly 2025 Decliners & Growth Oriented Trading Recommendations - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Applying big data sentiment scoring on Rapport Therapeutics Inc.Quarterly Profit Summary & Weekly Watchlist of Top Performers - newser.com
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Unveiling Its 93.40% Potential Upside in the Booming Biotech Sector - DirectorsTalk Interviews
Should you hold or exit Rapport Therapeutics Inc. nowMarket Trend Review & Real-Time Volume Analysis Alerts - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 2.3%What's Next? - MarketBeat
What analysts say about Rapport Therapeutics Inc stockStock Buy Signals & Invest Now – Opportunity Window Closing - earlytimes.in
Full technical analysis of Rapport Therapeutics Inc. stockJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Applying Elliott Wave Theory to Rapport Therapeutics Inc.Weekly Volume Report & Weekly Chart Analysis and Guides - newser.com
Momentum divergence signals in Rapport Therapeutics Inc. chartJuly 2025 Gainers & Weekly High Conviction Trade Ideas - newser.com
How institutional ownership impacts Rapport Therapeutics Inc. stockWeekly Trend Recap & Capital Efficient Trade Techniques - newser.com
Using data filters to optimize entry into Rapport Therapeutics Inc.July 2025 Closing Moves & Target Return Focused Stock Picks - newser.com
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Exploring an 81% Upside Potential in CNS Therapeutics - DirectorsTalk Interviews
Why Rapport Therapeutics Inc. stock could be next big winner2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
Is Rapport Therapeutics Inc. stock recession proofMarket Risk Report & Verified Short-Term Plans - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 7.3%Here's What Happened - MarketBeat
Why Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst Optimism - Yahoo Finance
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownTime to Sell? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading 4.3% HigherShould You Buy? - MarketBeat
JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success - Insider Monkey
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Es liegen keine Finanzdaten für Rapport Therapeutics Inc (RAPP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Rapport Therapeutics Inc-Aktie (RAPP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Sep 17 '25 |
Sale |
26.32 |
35,585 |
936,472 |
46,144 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):